Author: Mahrukh Rehan

Cellect Biotechnology Ltd. (APOP) is experiencing an increase of 59.09% in the aftermarket after announcing bone marrow transplantation of the first patient in the U.S. However, the last trading session closed at $5.5 with an increase of 6.8%.

Bone Marrow Transplantation of First Patient in the U.S by APOP

APOP announced on 2^nd September 2021 that the first ApoGraftTM transplantation in a Leukemia patient took place in the Company’s clinical trial at Washington University in St. Louis. ApoGraftTM is a product based on the company’s cell selection technology that is intended to improve immune treatment, specifically to avoid graft-versus-host disease (GVHD) after bone marrow transplantation.

ApoGraftTM development will be undertaken by EnCellX, a privately owned U.S.  business that is purchasing APOP’s unique technology.

The experiment will include 18 patients with hematological malignancies who will get a haploidentical bone marrow transplant (BMT). EnCellX, led by Adi Mohanty, is gathering funding from top healthcare institutional investors to accelerate and extend clinical development.

APOP Announced Second Quarter 2021 Financial Results

The Financial and operating results were announced on 24^th August 2021 for the second quarter which ended on June 30, 2021. The costs of research and development (R&D) were estimated to be $0.42 million while the total comprehensive loss was $1.7 million in the second quarter of 2021.

APOP also gave an update on the planned strategic merger with privately-owned Quoin Pharmaceuticals and recent clinical developments.

Top-Line Data from Phase 1/2 Clinical Trial

APOP reported good results from the ApoGraftTM technology’s open-label Phase 1/2 clinical study in Israel on 19^th April 2021. The ApoGraft product was used to transplant all eleven patients in the experiment, and they were all engrafted quickly.

The major goal of the research, to determine the safety and tolerability of ApoGraft in patients with hemato-oncology diseases, was fulfilled, and no procedure-related adverse events (AEs) were recorded.

Following the expected completion of the merger with Quoin Pharmaceuticals, the development of the ApoGraft technology is likely to be pursued by San Diego-based EnCellX, directed by Adi Mohanty.

APOP and Quoin Pharmaceuticals Announce Strategic Merger

On March 24, 2021, the Boards of Directors have unanimously approved a formal Merger Agreement. APOP shareholders will retain about 25% of the combined shares prior to investment, while Quoin owners will receive shares of APOP common stock representing approximately 75% of the shares, according to the provisions of the Agreement.

Moreover, Quoin has received $25 million in committed equity investment from Altium Capital and has secured an $18.5 million venture loan from a major commercial bank in the United States.

METX stock has experienced a decrease of 45.93% in the current market trading session. However, the last trading session was closed with an increase of 36.84%. Let’s study more about METX.

Launch of a New initiative to grow the blockchain and cryptocurrency industries by METX

On 1^st September 2021, the METX announced to launch of a new initiative to establish a blockchain and cryptocurrency business with the objective of making it a new standard among creative businesses.

Beginning in 2020, the company has been investigating the possibility of a blockchain and cryptocurrency business. The Company has created a blockchain technology strategy plan, aimed to introduce the Dogecoin reward system, and using non-fungible tokens (“NFT”) for digital copyright in online education.

The company aims to create new divisions and hire a competent team to push blockchain and cryptocurrency business in the next two to three months, based on its expertise with blockchain technology, NFT, and the Dogecoin reward system.

Announcement of Underwritten Public Offering of ordinary shares & pre-funded Warrants by METX

METX announced on 1^st September 2021 its intention to initiate a public offering of common stock and pre-funded warrants. Each pre-funded warrant shall be priced at $0.01 less than the ordinary shares. The net proceeds will be used to meet the Company’s general corporate and working capital needs.

Market Corporate Training and Expand Market Presence

On August 31, 2021, METX stated that it is working to expand its market position in the corporate training sector. As compared to the last year, METX’s gross billing of corporate training business increased by 107% from January to July of 2021. Also, the number of corporate workers serviced has grown by 53%, and the number of enterprise clients served has increased by 60%. Customer renewal rates exceeded 90%, and customer and student satisfaction rates exceeded 95%.

Greif, Inc. (GEF) experiences an increase of 2.83% in the premarket after GEF stock released its quarterly report. The stock concluded at $63.7 with a 0.6% increase in the last trading session.

GEF Stock’s Third Quarter 2021 Results

GEF stock, a global leader in industrial packaging products and services, released its third-quarter results for 2021 on 1^st September 2021. Net sales of $1,490.8 million set a new high, up to $407.8 million from last year’s $1,083.0 million.

In comparison to the net income of GEF Stock i.e., $20.7 million or $0.35 per diluted Class A share rose to $113.0 million or $1.89 per diluted Class A share. Net income was $115.9 million, or $1.93 per diluted Class A share, excluding the impact of adjustments, compared to net income of $50.1 million, or $0.85 per diluted Class A share, excluding the impact of adjustments.

To $2,267.6 million, total debt was reduced by $370.0 million. Net debt fell by $371.3 million to $2,167.8 million in the second quarter of 2021, and by $35.2 million sequentially. The Company’s leverage ratio dropped from 3.7x to 2.8x.

GEF Stock Announces Increase in Dividends for the third quarter of 2021

Greif’s Board of Directors declared enhanced quarterly cash dividends of $0.46 per share on Class A common stock and $0.69 per share on Class B common stock on August 31, 2021. In comparison to the fiscal second quarter of 2021 and the fiscal third quarter of 2020, this dividend declaration of GEF Stock reflects a 4.5 percent per share increase.

$70 Per Ton Price Increase by GEF Stock

On 11^th August 2021, Greif announced that it will increase the price of all grades of uncoated recycled paperboard (URB) by $70 per ton, as well as all tube and core and protective packaging goods by 8.5 percent.

The price rise for uncoated recycled paperboard goes into effect today, with new orders and shipments beginning on September 13, 2021. This is on top of the $50 per ton pricing hike that took effect on July 26, 2021. The increase in tube and core, as well as protective packaging, is effective for shipments on or after September 24, 2021. This is on top of the 6% price increase that took effect on August 6, 2021.

Conclusion

GEF’s stock future is bright, with earnings anticipated to more than quadruple in the next few years. Higher cash flow appears to be on the way for the company, which should lead to a higher share price.

Being a computational biological company, Evogene Ltd. (EVGN) experiences a gain of 2.32% in the premarket at the time of writing. However, the last trading session ended at $3.02 with an increase of 0.67%.

EVGN Announces 23rd Annual Global Investment Conference

On 1^st September 2021, it was announced that Ofer Haviv, Evogene’s President and CEO, will speak at the H.C. Wainwright 23rd Annual Global Investment Conference, 2021, from September 9 to 15, 2021. EVGN is a leading computational biology company striving to revolutionize life-science research and development across multiple market segments.

Pre-sale of Medical Cannabis Products of the First Generation

G-nnovation products will be offered to a small number of approved patients in Israel as part of the pre-launch through Telepharma pharmacy, which Canonic recently partnered with.

The pre-launch of medical cannabis was announced on the 31^st of August 2021 by EVGN.

The pre-launch comes after Canonic’s Meta Yield product program successfully completed the selection and development of the first-generation G-nnovation product line, as well as the approval of product files by the Israel Medical Cannabis Authority (IMCA) and the establishment of commercialization channels.

According to current figures by EVGN, roughly 100,000 approved patients consumed around 20 tons of cannabis in the first six months of 2021, with a total medical cannabis industry in Israel projected at $260 million per year. According to industry projections, the Israeli market will reach roughly 250,000 patients by 2025, depending on current growth rates.

EVGN releases financial results for 2021

It was declared on the 11^th of August 2021 that the overall net cash consumption in the first half of 2021 was about $11.3 million, or $8.9 million without Lavie Bio. These figures exclude $28 million in net proceeds from EVGN’s at-the-market (ATM) sales and $0.5 million in profits from option exercise. The overall cash consumption in the second quarter was $5.7 million, or $4.5 million without Lavie Bio.

Conclusion

The future of Evogene Ltd (EVGN) is bright since it is one of the high-yielding stocks. The “EVGN” stock price projection is 17.148 USD in the near future.